BALAD-2 score for the prediction of survival in patients with hepatocellular carcinoma.

e15091 Background: The prognosis of patients with hepatocellular carcinoma (HCC) is based on multiple factors. They include tumor related factors, liver function and patients´general health status. α-fetoprotein (AFP) is a valuable tool for the prediction of survival in patients with HCC, but is expressed in 60% of patients only. We evaluated a combination of AFP, AFP-L3 (lens culinaris agglutinin-reactive AFP) and des-gamma-carboxy prothrombin (DCP) (measured on a μTASWako i30 auto analyzer (Wako Chemicals GmbH, Neuss, Germany)) with bilirubin and albumin (BALAD-2 score) for the discrimination of survival in patients with HCC (Fox R, et al. Biomarkers based prognosis in hepatocellular Carcinoma: Validation and extension of the BALAD model. In Press.). Methods: In 106 patients with HCC (female n = 14, male n = 82, median age 69 years (y) (range 42-88y) the BALAD-2 score (0.02 x ([AFP] - 2.57) + 0.012 x ([AFP-L3] - 14.19) + 0.19 x (ln[DCP] - 1.93) + 0.17 x ([BIL]1/2 - 4.50) - 0.09 x ([ALB] - 35.11) was cal...